Report overview
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
Post-pandemic Era-Global Drugs for Non-Small Cell Lung Cancer Market Analysis 2022, With Top Companies, Sales, Revenue, Consumption, Price and Growth Rate?, which aims to sort out the development status and trends of the Drugs for Non-Small Cell Lung Cancer industry at home and abroad, estimate the overall market scale of the Drugs for Non-Small Cell Lung Cancer industry and the market share of major countries, Drugs for Non-Small Cell Lung Cancer industry, and study and judge the downstream market demand of Drugs for Non-Small Cell Lung Cancer through systematic research, Analyze the competition pattern of Drugs for Non-Small Cell Lung Cancer, so as to help solve the pain points of various stakeholders in Drugs for Non-Small Cell Lung Cancer industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018- 2028) of Drugs for Non-Small Cell Lung Cancer Market by Research Include
NorthAmerica
Asia
Europe
Middle East & Africa
South America
Competitive Analysis; Who are the Major Players in Drugs for Non-Small Cell Lung Cancer Market?
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
Ziopharm Oncology
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Major Type of Drugs for Non-Small Cell Lung Cancer Covered in Research report:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy
Application Segments Covered in Research Market
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
